Bill Gives Small-Molecule Drugs More Time On Market Before Negotiation

House Energy & Commerce health subcommittee chair Brett Guthrie (R-KY) wants to address what he believes is unfair treatment of small-molecule drugs under the Inflation Reduction Act through new bipartisan legislation introduced Friday (Feb. 2) that would extend how long small-molecule drugs have following entry into the market before CMS can consider them eligible to be selected for drug price negotiation. Currently, the IRA states that small molecule drugs are eligible for drug price negotiation in Medicare seven years after...